StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

Equities researchers at StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report released on Thursday. The firm set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Stock Up 0.7 %

Shares of BTX opened at $6.72 on Thursday. Brooklyn ImmunoTherapeutics has a 52 week low of $6.57 and a 52 week high of $8.31. The company has a market capitalization of $395.31 million, a price-to-earnings ratio of -2.96 and a beta of 4.61. The stock’s 50-day moving average price is $2.01 and its 200-day moving average price is $1.35.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.